A randomized phase II study of recombinant human endostatin plus gemcitabine/cisplatin compared with gemcitabine/cisplatin alone as first-line therapy in advanced non-small-cell lung cancer
- 287 Downloads
Purpose Studies indicate that recombinant human endostatin (rh-endostatin) can inhibit tumor endothelial cell proliferation, angiogenesis, and tumor growth. This study assessed the efficacy of the combination of standard gemcitabine plus cisplatin chemotherapy with rh-endostatin in patients with non-small-cell lung cancer (NSCLC). Patients and Methods Chemotherapy-naive patients with stage IIIB to IV NSCLC were randomly (1:1) assigned to receive gemcitabine/cisplatin chemotherapy alone or with 7.5 mg/ m2 of intravenously rh-endostatin on days 1 to 14 of each 3-week cycle. The primary end point was objective response rate (ORR). Results Baseline characteristics were similar between treatment arms. The best ORRs for rh-endostatin arm (n = 33) and chemotherapy-alone arm were 37.5% (95% CI: 21.3 to 47.2%) and 28.6% (95% CI: 19.8 to 37.6%), respectively. Median survival was 12.4 months in the rh-endostatin arm and 9.8 months in the chemotherapy-alone arm, and 1-year survival was 51.6% and 38.7%, respectively. Mild palpitions, diarrhea, and liver dysfunction were the most common rh-endostatin-related adverse events. Grade 3/4 hematological toxicities were all reported similar for patients in the two arms. Conclusion The addition of rh-endostatin to gemcitabine plus cisplatin chemotherapy for first-line treatment of NSCLC improves objective response and may improve survival.
KeywordsToxicity Chemotherapy Cancer Response rate Non-small-cell lung cancer
The authors wish to thank all the patients who chose to participate in this trial.
- 7.Iizasa T, Chang H, Suzuki M, et al (2005) Expression of collagen XVIII in non-small cell lung carcinoma and its prognostic value. AACR Meeting Abstracts, 944Google Scholar
- 9.Sun Y, Wang J, Liu Y, et al (2005) Results of phase III trial of rh-endostatin (YH-16) in advanced non-small cell lung cancer (NSCLC) patients. ASCO Meeting Abstracts :7138Google Scholar
- 10.Han B, Xiu Q, Wang H, et al (2008) Rh-endostatin injection plus paclitaxel and carboplatin therapy for non-small-cell lung cancer: randomized, double-blind, placebo-controlled, multicentre study. ASCO Meeting Abstracts :19126Google Scholar
- 12.Arrieta O, González-De la Rosa CH, Aréchaga-Ocampo E et al (2010) Randomized phase II trial of all-trans-retinoic acid with chemotherapy based on paclitaxel and cisplatin as first-line treatment in patients with advanced non-small-cell lung cancer. J Clin Oncol 28:3463–3471PubMedCrossRefGoogle Scholar